HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: Results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte

Coronary Artery Disease

Volumn 9, Issue 5, 1998, Pages 265-272

  Von Essen, Rainer ^a   Zeymer, Uwe ^b   Tebbe, Ulrich ^c   Jessel, Andreas ⁱ   Kwasny, Harald ⁱ   Mateblowski, Michael ⁱ   Niederer, Walter ^d   Wagner, Joachim ^e   Mäurer, Wolfgang ^f   Von Leitner, Enz Rüdiger ^g   Haerten, Klaus ^h   Roth, Michael ^a   Neuhaus, Karl Ludwig ^b,h  

^a 2nd Medical Clinic   (Germany)

^b KLINIKUM KASSEL   (Germany)

^c KLINIKUM LIPPE DETMOLD   (Germany)

^d Krankhs Barmherzigen Bruder R   (Germany)

^e Stadtisches Krankhs Berlin Neukolln   (Germany)

^f INSTITUTE OF PATHOLOGY   (Germany)

^g Krankenhaus Siloah   (Germany)

^h MARIEN HOSPITAL WESEL   (Germany)

ⁱ Behringwerke AG   (Germany)

Author keywords

Acute myocardial infarction; Clinical trials; Hirudin; Thrombolysis

Indexed keywords

ALTEPLASE; LEPIRUDIN; RECOMBINANT PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTERY OCCLUSION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE CALCULATION; DRUG INFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 15444340960     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809050-00004     Document Type: Article

References (22)

1. Ohman EM, Calliff RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, et al., for the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82:781-791.
2. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel K-F, Neuhaus K-L. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391-1395.
3. Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase. Results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992; 19:885-891.
4. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682.
5. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991; 83:937-944.
6. Prins MH, Hirsh J. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991; 67:3A-11A.
7. Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, et al. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989; 74:1025-1030.
8. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83:1048-1056.
9. Goldmann AI. Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Controlled Clin Trials 1987; 8:327-338.
10. Hartung J. Statistik. München: Oldenbourg Verlag; 1985. pp. 251-258.
11. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. New Engl J Med 1985; 312: 932-936.
12. Armitage P. Test for linear trend in proportions and frequencies. Biometrics 1955; 11:375-386.
13. Breslow NE, Day NE. The analysis of case-control studies. IARC Scientific Publications, No. 32. Lyon, France: IARC Scientific Publications; 1980.
14. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994; 90:1638-1642.
15. Cannon C, McCabe C, Henry T, Schweiger MJ, Gibson RS, Mueller HS, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23:993-1003.
16. Antman EM, for the TIMI 9B Investigators. Hirudin in acute mycardial infarction. TIMI 9B trial. Circulation 1996; 94:911-921.
17. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335:775-782.
18. Neuhaus KL, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner H-J, et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol 1994; 24:55-60.
19. Markwardt F. The development of Hirudin as an anticoagulant agent. Curr Opin Ther Patents 1991; (July):981-995.
20. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994; 89:1545-1556.
21. von Essen R, Effert S, Silny J, Rau G, Kruse E. Das EKG beim akuten Myokardinfarkt. Kontinuierliche Registrierung während des thrombolytischen Therapie. Z Kardiol 1990, 79:819-824.
22. Schröder R, Dissmann R, Brüggemann T, Wegscheider K, Linderer T, Tebbe U, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24:384-391.